Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 22, 2026
TickeronGET DAILY SIGNALS
Harmony Biosciences (HRMY): Path to $47 Target and +44% Upside Potential

Harmony Biosciences (HRMY): Path to $47 Target and +44% Upside Potential

Key Takeaways

  • The central $47 price target is the arithmetic mean of 12 verified analyst price targets reviewed for Harmony Biosciences Holdings, Inc. (HRMY), calculated at roughly $46.50 and rounded to $47.
  • Individual analyst targets span a wide range from $28 (Bank of America) to $72 (Oppenheimer), reflecting sharply divided views on the stock's patent risk and pipeline optionality.
  • With shares recently trading near $32.59, reaching $47 would require an upside of roughly 44% — a very large move by any conventional standard.
  • The strongest support comes from accelerating demand for flagship drug WAKIX, with full-year 2026 net revenue guidance of $1.0 billion to $1.04 billion.
  • The biggest risk is the pending AET patent litigation, which could materially shorten WAKIX's exclusivity, along with a recent Q3 2026 earnings miss and a CEO transition.
  • For the latest developments, explore Major News, Today's Price Move, the Forecast, and upcoming Earnings pages on Tickeron.
  • To see AI-driven trading ideas across the market, explore Trending AI Robots.

Breaking Down the Analyst Targets for HRMY

The $47 central target reflects a review of 12 current, attributable analyst price targets, which range from a low of $28 (Bank of America, Sell-rated) to a high of $72 (Oppenheimer). The arithmetic mean of these figures is approximately $46.50, which rounds to $47 — a level in line with widely cited aggregator averages in the $47–$49 range. This is a calculated mean, not an official published consensus.

Views differ sharply. Bullish targets cluster between $46 and $60, including H.C. Wainwright ($55, Buy), Ladenburg Thalmann ($55, initiated Buy in October 2026), Needham ($50), Mizuho ($49), Wolfe Research ($60, initiated Buy), and Piper Sandler ($46). More cautious voices include UBS ($39, Hold), Deutsche Bank ($42, Hold), Goldman Sachs ($33, Hold), and Truist ($29, Hold), while Bank of America stands alone at $28 with a Sell rating. The gap largely reflects differing assumptions about how durable WAKIX's exclusivity proves to be.

Where HRMY Stands Today and the Road to $47

HRMY shares last traded near $32.59, leaving a required gain of roughly 44% to reach $47. That is a very large move, meaning the stock would need to not only retake but exceed its 52-week high of about $43.49.

Fundamentals are improving in parts. Third-quarter 2026 WAKIX net revenue rose to $269 million from $239 million a year earlier, with 400 net patient adds and roughly 9,350 average patients on therapy. Management reiterated full-year 2026 WAKIX revenue guidance of $1.0 billion to $1.04 billion — the first time annual sales would top $1 billion. Yet Q3 EPS of $0.81 missed the roughly $1.00 consensus, and the company announced CEO Jeffrey Dayno's retirement effective December 31, 2026, with COO Peter Anastasiou succeeding him.

Factors That Could Drive HRMY Higher

  • Continued WAKIX demand growth, supported by its position as a non-controlled treatment for narcolepsy with broad payer coverage.
  • A strong balance sheet exceeding $1 billion, funding pipeline advancement and potential business development.
  • Encouraging multiple-ascending dose data for BP-205, an orexin-2 agonist viewed as a potential best-in-class asset, with Phase 2 studies planned for mid-2027.
  • Settlements reached with six of seven ANDA (abbreviated new drug application) filers, reinforcing confidence in WAKIX exclusivity into March 2030.
  • An inexpensive valuation — a trailing P/E (price-to-earnings ratio) in the low double digits — for a profitable, growing biotech.

Key Risks on the Horizon

  • The outstanding AET patent litigation over the pitolisant franchise represents the single largest overhang; an adverse ruling could accelerate generic competition.
  • A Q3 2026 earnings miss on higher costs signals potential margin pressure even as revenue grows.
  • Concentration risk: WAKIX still accounts for nearly all revenue, leaving the company exposed to a single asset.
  • Executive transition can unsettle investors, as reflected in the stock's decline following the CEO succession announcement.
  • Wider biotech and interest-rate conditions could compress valuations even if company fundamentals hold.

Technical Outlook for HRMY

The stock's 52-week range sits between roughly $25.52 and $43.49. Current levels near $32.59 place HRMY in the lower half of that range. The $43–$44 zone, anchored by the prior high, stands as the first major resistance level, followed by the psychological $50 mark. On the downside, the $25.50–$26 area has acted as durable support. A sustained move toward $47 would require clearing the prior high and confirming a breakout on volume. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What to Watch Going Forward

Analyst price targets typically reflect a roughly 12-month research horizon, though the exact horizon varies by firm. Key items to monitor include the resolution of the AET patent litigation, any further updates on the WAKIX franchise, BP-205 clinical readouts (Phase 1 sleep-deprivation data expected in early 2027), the CEO transition, and future earnings reports that test whether the company can deliver EPS growth alongside revenue expansion. Analyst revisions following these events will matter more than the headline target itself.

My Take on the $47 Target

The question of whether HRMY can reach $47 hinges on a calculated mean of analyst targets spanning $28 to $72 — a range that underscores genuine disagreement about the stock's future. Achieving the target would require a roughly 44% advance, a very large move that would demand both continued WAKIX growth and a favorable resolution of the patent overhang. Bullish analysts emphasize accelerating sales, a strong balance sheet, and BP-205's optionality, while bears focus on litigation risk, the Q3 earnings miss, and single-asset concentration. The balance of evidence points to a credible but by no means assured path, and investors should monitor the patent case, pipeline data, and earnings trajectory closely before drawing conclusions.

Exploring AI Daily Buy/Sell Signals

In my own analysis, I find Tickeron's AI Daily Buy/Sell Signals helpful for tracking shifts in stocks like HRMY. The tool applies AI to monitor market conditions and technical behavior, offering Buy, Sell, or Hold signals that complement fundamental research and analyst targets. It has become a regular part of how I review opportunities without replacing deeper due diligence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HRMY

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


HRMY's RSI Indicator climbs out of oversold territory

The RSI Oscillator for HRMY moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 27 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +0.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRMY advanced for three days, in 206 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

HRMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HRMY as a result. In 73 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for HRMY turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 32 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

The Aroon Indicator for HRMY entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. HRMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.930) is normal, around the industry mean (3.596). P/E Ratio (10.578) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (2.581) is also within normal values, averaging (443.347).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders

Industry Biotechnology

Industry
N/A
Address
630 W. Germantown Pike
Phone
+1 484 539-9800
Employees
293
Web
https://www.harmonybiosciences.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.